Medical Science
| Open Access |
DOI: Clinical, Morphological, And Immunolaboratory Characteristics of Types of Chronic Glomerulonephritis Resistant to Pathogenetic Therapy
Yusupov Mukhammadsardor Mukhammadsolih ugli , Nephrologist in The Department of Autoimmune Diseases at The Republican Specialized Scientific and Practical Medical Center of Nephrology and Kidney Transplantation, Uzbekistan Abdullayev Sherzod Sadullaevich , Associate Professor, Head of The Scientific Department of Immunogenetics At the Republican Specialized Scientific and Practical Medical Center of Nephrology and Kidney Transplantation, UzbekistanAbstract
This review article examines the clinical, morphological, structural, and functional changes, as well as the immunolaboratory characteristics and treatment challenges associated with chronic glomerulonephritis resistant to pathogenetic therapy. It also outlines the fundamental principles for treating refractory glomerulonephritis, alongside research and considerations from recent decades. Furthermore, it identifies various areas of research needed for the treatment of refractory glomerulonephritis.
Keywords
Chronic glomerulonephritis, glucocorticosteroid, immunity
References
Boumediene A. et al. NEPHRUTIX: A randomized, doubleblind, placebo vs. Rituximab- controlled trial assessing T-cell subset changes in Minimal Change Nephrotic Syndrome. J Autoimmun. 2018; 88: 91–102. DOI: 10.1016/j.jaut.2017.10.006
Candelier J.J. et al. Idiopathic nephrotic syndrome and serum permeability factors: a molecular jigsaw puzzle. Cell Tissue Res 2020;379 (2):231-243. doi: 10.1007/s00441-019-03147-y
Dall'Era M. et al. Autoimmunity Centers of Excellence. Adoptive Treg Cell Therapy in a Patient With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019; 71 (3): 431–440. DOI: 10.1002/art.40737
Diefenhardt P. et al. IL-10 Receptor signaling empowers regulatory T cells to control Th17 responses and protect from GN. J. Am. Soc. Nephrol., 2018, Vol. 29, no. 7, pp. 1825-1837.
Janphram C. et al. Years of life lost and long-term outcomes due to glomerular disease in a Southeast Asian Cohort. Sci Rep. 2023; 13 (1): 19119.
Karzakova L.M. et al. Fundamentals of General Immunology: a textbook. Cheboksary: Chuvash University Publishing House, 2020. 200 p.
Karzakova L.M. et al. Study of clinical and immunological associations of primary glomerulonephritis. Modern problems of science and education. 2019; (6): 116. DOI: 10.17513/spno.29298
Khandelwal P. et al. CD38brightCD8+ T Cells Associated with the Development of Acute GVHD Are Activated, Proliferating, and Cytotoxic Trafficking Cells. Biol. Blood Marrow Transplant. 2020; 26: 1–6. DOI: 10.1016/j.bbmt.2019.08.008
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021; 100 (4S): S1–S276. DOI: 10.1016/j.kint.2021.05.021
Kudryashov S.I. et al. A new approach to immunosuppressive therapy in patients with glomerulonephritis with nephrotic syndrome. Medical Immunology. 2024; 26 (1): 181-190. doi: 10.15789/1563-0625-ANA-2670
Kudryashov S.I. et al. Features of the immune status in patients with glomerulonephritis with refractory nephrotic syndrome. Bulletin of Modern Clinical Medicine. 2024; 17 (1): 22–28. DOI: 10.20969/VSKM.2024.17 (1).22-28.
Li Y. et al. Low-dose IL-2 expands CD4+ regulatory T cells with a suppressive function in vitro via the STAT5-dependent pathway in patients with chronic kidney diseases. Ren. Fail., 2018, Vol. 40, no. 1, pp. 280-288.
Marangoni F. et al. Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop. Cell, 2021, Vol. 184, no. 15, pp. 3998-4015.e19.
Motavalli R. et al. Altered Th17/Treg ratio as a possible mechanism in pathogenesis of idiopathic membranous nephropathy. Cytokine. 2021; 141: e155452. DOI: 10.1016/j.cyto.2021.155452
Motavalli R. et al. Immune system- mediated cellular and molecular mechanisms in idiopathic membranous nephropathy pathogenesis and possible therapeutic targets. Life Sci. 2019; 238: e116923. DOI: 10.1016/j.lfs.2019.116923
Rosenzwajg M. et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann. Rheum. Dis., 2019, Vol. 78, no. 2, pp. 209-217.
So L. et al. Regulatory T cells suppress CD4+ effector T cell activation by controlling protein synthesis. J Exp Med. 2023; 220 (3): e20221676. DOI: 10.1084/jem.20221676
Tran G.T. et al. Autoantigen specific IL-2 activated CD4+CD25+T regulatory cells inhibit induction of experimental autoimmune neuritis. J. Neuroimmunol., 2020, Vol. 15, no. 341, 577186. doi: 10.1016/j.jneuroim.2020.577186.
Von Groote T.C. et al. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst. Rev., 2021, Vol. 11, no. 11, CD004293. doi: 10.1002/14651858.CD004293.pub4.
Yang C. et al. The Regulatory T-cell Transcription Factor Foxp3 Protects against Crescentic Glomerulonephritis. Sci. Rep., 2017, Vol. 7, 1481. doi: 10.1038/s41598-017-01515-8.
Download and View Statistics
Copyright License
Copyright (c) 2026 Yusupov Mukhammadsardor Mukhammadsolih ugli, Abdullayev Sherzod Sadullaevich
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.